Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
We read with interest the article by James F. Donohue et al, which summarized the results of two identical studies on the once-daily (od) long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination, vilanterol (VIL)/umeclidinium (UMEC) and the twice-daily (bid) LABA/inhaled corticosteroid (ICS) combination salmeterol (SAL)/fluticasone propionate (FP). The primary endpoint was least squares mean change from baseline in 0 to 24-h weighted mean FEV1 versus FP/SAL on Day 84 in patients with moderate-to-severe COPD, without a documented history of COPD exacerbation in the year before screening [1].
Source: Respiratory Medicine CME - Category: Respiratory Medicine Authors: Donald Banerji, Francesco Patalano Tags: Correspondence Source Type: research
More News: Advair | Advair Diskus | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Flonase | Flovent | Respiratory Medicine | Study